STAT3 and non-small cell lung carcinoma: Hence, our studies discovered a novel STAT3 inhibitor W2014-S with potent antitumor activities in NSCLC and suggested that the combination of STAT3 inhibitor with gefitinib could serve as a promising strategy to overcome EGFR-TKIs resistance in NSCLC patients.